Ilya Rachman
Chief Executive Officer chez IMMIX BIOPHARMA, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Ilya Rachman is a Chairman & Chief Executive Officer and founder of Immix Biopharma, Inc. which is founded in 2012.
He is also currently an Executive Chairman at Nexcella, Inc. Dr. Rachman has an MBA from the University of California, Los Angeles, a graduate and doctorate degree from the University of Illinois, and an undergraduate degree from the University of Iowa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMIX BIOPHARMA, INC.
3,53% | 14/08/2023 | 902 500 ( 3,53% ) | 3 M $ | 31/03/2024 |
Postes actifs de Ilya Rachman
| Sociétés | Poste | Début |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Chief Executive Officer | 01/01/2012 |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Chairman | - |
Formation de Ilya Rachman
| University of California, Los Angeles | Masters Business Admin |
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
